BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

812 related articles for article (PubMed ID: 31255741)

  • 21. Oral vancomycin prophylaxis against recurrent
    Zacharioudakis IM; Zervou FN; Dubrovskaya Y; Phillips MS
    Infect Control Hosp Epidemiol; 2020 Aug; 41(8):908-913. PubMed ID: 32539877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of oral vancomycin prophylaxis for prevention of
    Tariq R; Laguio-Vila M; Tahir MW; Orenstein R; Pardi DS; Khanna S
    Therap Adv Gastroenterol; 2021; 14():1756284821994046. PubMed ID: 33747124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence, course, and outcome of Clostridium difficile infection in children with hematological malignancies or undergoing hematopoietic stem cell transplantation.
    Salamonowicz M; Ociepa T; Frączkiewicz J; Szmydki-Baran A; Matysiak M; Czyżewski K; Wysocki M; Gałązka P; Zalas-Więcek P; Irga-Jaworska N; Drożyńska E; Zając-Spychała O; Wachowiak J; Gryniewicz-Kwiatkowska O; Czajńska-Deptuła A; Dembowska-Bagińska B; Chełmecka-Wiktorczyk L; Balwierz W; Bartnik M; Zielezińska K; Urasiński T; Tomaszewska R; Szczepański T; Płonowski M; Krawczuk-Rybak M; Pierlejewski F; Młynarski W; Gamrot-Pyka Z; Woszczyk M; Małas Z; Badowska W; Urbanek-Dądela A; Karolczyk G; Stolpa W; Sobol-Milejska G; Zaucha-Prażmo A; Kowalczyk J; Goździk J; Gorczyńska E; Jermakow K; Król A; Chybicka A; Ussowicz M; Kałwak K; Styczyński J
    Eur J Clin Microbiol Infect Dis; 2018 Sep; 37(9):1805-1812. PubMed ID: 29978303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections.
    Carignan A; Poulin S; Martin P; Labbé AC; Valiquette L; Al-Bachari H; Montpetit LP; Pépin J
    Am J Gastroenterol; 2016 Dec; 111(12):1834-1840. PubMed ID: 27619835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clostridioides difficile infection in immunocompromised hospitalized patients is associated with a high recurrence rate.
    Avni T; Babitch T; Ben-Zvi H; Hijazi R; Ayada G; Atamna A; Bishara J
    Int J Infect Dis; 2020 Jan; 90():237-242. PubMed ID: 31672656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clostridium difficile infection in the hematopoietic unit: a meta-analysis of published studies.
    Zacharioudakis IM; Ziakas PD; Mylonakis E
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1650-4. PubMed ID: 24914822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors and epidemiology of Clostridium difficile infection in hematopoietic stem cell transplant recipients during the peritransplant period.
    Aldrete SD; Kraft CS; Magee MJ; Chan A; Hutcherson D; Langston AA; Greenwell BI; Burd EM; Friedman-Moraco R
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clostridioides (Clostridium) difficile infection in Japanese hospitals 2008-2017: A real-world nationwide analysis of treatment pattern, incidence and testing density.
    Kimura T; Stanhope S; Sugitani T
    J Infect Chemother; 2020 May; 26(5):438-443. PubMed ID: 32081648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for the development of Clostridium difficile infection in adult allogeneic hematopoietic stem cell transplant recipients: A single-center study in Québec, Canada.
    Lavallée C; Labbé AC; Talbot JD; Alonso CD; Marr KA; Cohen S; Laverdière M; Dufresne SF
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections.
    Rao K; Zhao Q; Bell J; Krishnan J; Henig O; Daniel J; Sawaya K; Albin O; Mills JP; Petty LA; Gregg K; Kaul D; Malani AN; Pogue J; Kaye KS
    Clin Infect Dis; 2024 Feb; 78(2):277-282. PubMed ID: 37797310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of fidaxomicin versus oral vancomycin in the treatment of recurrent clostridioides difficile.
    Rinaldi A; Reed EE; Stevenson KB; Coe K; Smith JM
    J Clin Pharm Ther; 2021 Aug; 46(4):993-998. PubMed ID: 33609052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.
    Huang AM; Marini BL; Frame D; Aronoff DM; Nagel JL
    Transpl Infect Dis; 2014 Oct; 16(5):744-50. PubMed ID: 25040545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does Addition of Intravenous Metronidazole to Oral Vancomycin Improve Outcomes in Clostridioides difficile Infection?
    Wang Y; Schluger A; Li J; Gomez-Simmonds A; Salmasian H; Freedberg DE
    Clin Infect Dis; 2020 Dec; 71(9):2414-2420. PubMed ID: 31714955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and risk factors for recurrent
    Baldassarre L; Quach-Thanh C; Mouajou Feujio V; Tadount F; Deyirmendjian C; Lefebvre MA; Thampi N; Schneider O; Fabri-Karam I; O'Donnell S; Okeny-Owere J; Audy N; Desmarais N
    Infect Control Hosp Epidemiol; 2024 Feb; 45(2):182-187. PubMed ID: 37700539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clostridioides difficile infection in patients with hematological malignancy: A multicenter study in Taiwan.
    Hung YP; Tsai CS; Tsai BY; Tsai PJ; Lee YT; Lee JC; Liu HC; Hsueh PR; Lee CC; Ko WC
    J Microbiol Immunol Infect; 2021 Dec; 54(6):1101-1110. PubMed ID: 33678554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of oral vancomycin treatment duration on rate of
    Kwiatkowski D; Marsh K; Katz A; Papadopoulos J; So J; Major VJ; Sommer PM; Hochman S; Dubrovskaya Y; Arnouk S
    Infect Control Hosp Epidemiol; 2024 Jun; 45(6):717-725. PubMed ID: 38288606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significance of a positive Clostridium difficile toxin test after hematopoietic stem cell transplantation.
    Akahoshi Y; Kimura S; Nakano H; Harada N; Kameda K; Ugai T; Wada H; Yamasaki R; Ishihara Y; Kawamura K; Sakamoto K; Ashizawa M; Sato M; Terasako-Saito K; Nakasone H; Kikuchi M; Yamazaki R; Kanda J; Kako S; Nishida J; Kanda Y
    Clin Transplant; 2016 Jun; 30(6):703-8. PubMed ID: 27019071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.
    Webb BJ; Brunner A; Ford CD; Gazdik MA; Petersen FB; Hoda D
    Transpl Infect Dis; 2016 Aug; 18(4):628-33. PubMed ID: 27214585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
    Madoff SE; Urquiaga M; Alonso CD; Kelly CP
    Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
    Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.